PubMed

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.

Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, Kuritzkes DR, Reeves JD; AIDS Clinical Trials Group A5211 Team.

J Infect Dis. 2009 Dec 1;200(11):1724-8.PMID: 19874179 [PubMed - in process]Related articles

Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects.

Gupta SK, Komarow L, Gulick RM, Pollard RB, Robbins GK, Franceschini N, Szczech LA, Koletar SL, Kalayjian RC.

J Infect Dis. 2009 Aug 15;200(4):614-8.PMID: 19591572 [PubMed - indexed for MEDLINE]Related articles

Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions.

Hosoya N, Su Z, Wilkin T, Gulick RM, Flexner C, Hughes MD, Skolnik PR, Giguel F, Greaves WL, Coakley E, Kuritzkes DR.

J Clin Microbiol. 2009 Aug;47(8):2604-6. Epub 2009 Jun 3.PMID: 19494074 [PubMed - indexed for MEDLINE]Related articles

Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.

Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, Leitner T, Gaschen B, Theiler J, Paredes R, Su Z, Hughes MD, Gulick RM, Greaves W, Coakley E, Flexner C, Nusbaum C, Kuritzkes DR.

PLoS One. 2009 May 25;4(5):e5683.PMID: 19479085 [PubMed - indexed for MEDLINE]Related articlesFree article

Raltegravir: the first HIV type 1 integrase inhibitor.

Hicks C, Gulick RM.

Clin Infect Dis. 2009 Apr 1;48(7):931-9. Review.PMID: 19231980 [PubMed - indexed for MEDLINE]Related articles

Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.

Tsibris AM, Paredes R, Chadburn A, Su Z, Henrich TJ, Krambrink A, Hughes MD, Aberg JA, Currier JS, Tashima K, Godfrey C, Greaves W, Flexner C, Skolnik PR, Wilkin TJ, Gulick RM, Kuritzkes DR.

Clin Infect Dis. 2009 Mar 1;48(5):642-9.PMID: 19191652 [PubMed - indexed for MEDLINE]Related articlesFree article

Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals.

Charles M, Noel F, Leger P, Severe P, Riviere C, Beauharnais CA, Miller E, Rutledge J, Bang H, Shealey W, D'Aquila RT, Gulick RM, Johnson WD Jr, Wright PF, Pape JW, Fitzgerald DW.

Bull World Health Organ. 2008 Dec;86(12):970-7.PMID: 19142298 [PubMed - indexed for MEDLINE]Related articlesFree article

When to start antiretroviral therapy?

Wilkin TJ, Gulick RM.

Clin Infect Dis. 2008 Dec 15;47(12):1580-6. Review.PMID: 18990069 [PubMed - indexed for MEDLINE]Related articles

Maraviroc for previously treated patients with R5 HIV-1 infection.

Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1429-41.PMID: 18832244 [PubMed - indexed for MEDLINE]Related articlesFree article

In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.

Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, Subramanian M, Flexner C, Giguel F, Leopold KE, Coakley E, Kuritzkes DR.

J Virol. 2008 Aug;82(16):8210-4. Epub 2008 May 21.PMID: 18495779 [PubMed - indexed for MEDLINE]Related articlesFree article

Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.

Anderson JA, Jiang H, Ding X, Petch L, Journigan T, Fiscus SA, Haubrich R, Katzenstein D, Swanstrom R, Gulick RM; AIDS Clinical Trials Group Study 359 Protocol Team.

AIDS Res Hum Retroviruses. 2008 May;24(5):685-94.PMID: 18462083 [PubMed - indexed for MEDLINE]Related articles

Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.

Ribaudo HJ, Kuritzkes DR, Lalama CM, Schouten JT, Schackman BR, Acosta EP, Gulick RM.

J Infect Dis. 2008 Apr 1;197(7):1006-10.PMID: 18419537 [PubMed - indexed for MEDLINE]Related articles

Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.

Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA 3rd, Shikuma C, Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP, Gulick RM.

J Infect Dis. 2008 Mar 15;197(6):867-70.PMID: 18269317 [PubMed - indexed for MEDLINE]Related articles

Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.

Murphy RL, da Silva BA, Hicks CB, Eron JJ, Gulick RM, Thompson MA, McMillan F, King MS, Hanna GJ, Brun SC.

HIV Clin Trials. 2008 Jan-Feb;9(1):1-10.PMID: 18215977 [PubMed - indexed for MEDLINE]Related articlesFree article

Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.

Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM.

J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):547-54.PMID: 18193496 [PubMed - indexed for MEDLINE]Related articles

A comparison of three initial antiretroviral AIDS regimens.

Ribaudo HJ, Kuritzkes DR, Gulick RM.

N Engl J Med. 2007 Sep 6;357(10):1056-7. No abstract available. PMID: 17804858 [PubMed - indexed for MEDLINE]Related articles

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR; AIDS Clinical Trials Group 5211 Team.

J Infect Dis. 2007 Jul 15;196(2):304-12. Epub 2007 Jun 5.PMID: 17570119 [PubMed - indexed for MEDLINE]Related articles

Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359.

Haubrich RH, Jiang H, Swanstrom R, Bates M, Katzenstein D, Petch L, Fletcher CV, Fiscus SA, Gulick RM; AIDS Clinical Trials Group Protocol 359 Team.

HIV Clin Trials. 2007 Mar-Apr;8(2):63-7.PMID: 17507321 [PubMed - indexed for MEDLINE]Related articlesFree article

Antiretroviral management of treatment-naive patients.

Gulick RM.

Infect Dis Clin North Am. 2007 Mar;21(1):71-84, viii.PMID: 17502230 [PubMed - indexed for MEDLINE]Related articles

New antiretroviral agents.

Siegel L, Gulick RM.

Curr Infect Dis Rep. 2007 May;9(3):243-51.PMID: 17430707 [PubMed - in process]Related articles

Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.

Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR.

AIDS. 2007 Apr 23;21(7):813-23.PMID: 17415036 [PubMed - indexed for MEDLINE]Related articles

Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.

Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, Reichman R, Shikuma C, Meyer WA 3rd, Klingman KL, Gulick RM; ACTG A5166s Protocol Team.

J Infect Dis. 2007 Apr 15;195(8):1169-76. Epub 2007 Mar 6.PMID: 17357053 [PubMed - indexed for MEDLINE]Related articles

Design issues in initial HIV-treatment trials: focus on ACTG A5095.

Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RM.

Antivir Ther. 2006;11(6):751-60.PMID: 17310819 [PubMed - indexed for MEDLINE]Related articles

Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).

Shikuma CM, Yang Y, Glesby MJ, Meyer WA 3rd, Tashima KT, Ribaudo HJ, Webb N, Bastow B, Kuritzkes DR, Gulick RM.

J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):540-50.PMID: 17245230 [PubMed - indexed for MEDLINE]Related articles

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM.

Clin Infect Dis. 2007 Feb 15;44(4):591-5. Epub 2007 Jan 17. Erratum in: Clin Infect Dis. 2007 May 15;44(10):1399. PMID: 17243065 [PubMed - indexed for MEDLINE]Related articles

Switching antiretroviral therapy: why, when and how.

Wilkin T, Glesby M, Gulick RM.

IAPAC Mon. 2006 Jul;12(7):220-9. No abstract available. PMID: 17096494 [PubMed - indexed for MEDLINE]Related articles

A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.

Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, Gulick RM, Glesby MJ, Wantman M, Bixby CJ, Rinehart AR, Snyder S, Wang R, Patel S, Mellors JW; ACTG A5086 Study Team.

J Infect Dis. 2006 Nov 1;194(9):1309-18. Epub 2006 Sep 22.PMID: 17041858 [PubMed - indexed for MEDLINE]Related articles

Adherence to antiretroviral therapy: how much is enough?

Gulick RM.

Clin Infect Dis. 2006 Oct 1;43(7):942-4. Epub 2006 Aug 23. No abstract available. PMID: 16941381 [PubMed - indexed for MEDLINE]Related articles

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team.

JAMA. 2006 Aug 16;296(7):769-81.PMID: 16905783 [PubMed - indexed for MEDLINE]Related articlesFree article

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.

Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP; Adult AIDS Clinical Trials Group Study.

Clin Infect Dis. 2006 Feb 1;42(3):401-7. Epub 2005 Dec 27.PMID: 16392089 [PubMed - indexed for MEDLINE]Related articles

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.

Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaudo H, Gulick RM.

Ann Intern Med. 2005 Nov 15;143(10):714-21.PMID: 16287792 [PubMed - indexed for MEDLINE]Related articlesFree article

Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus.

Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ.

J Infect Dis. 2005 Dec 1;192(11):1943-9. Epub 2005 Nov 2.PMID: 16267765 [PubMed - indexed for MEDLINE]Related articles

The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects.

Clifford DB, Evans SR, Yang Y, Gulick RM.

AIDS. 2005 Oct;19 Suppl 3:S64-71.PMID: 16251830 [PubMed - indexed for MEDLINE]Related articles

Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359.

Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta EP, Martinez A, Jiang H, Gulick RM.

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):301-6.PMID: 16249704 [PubMed - indexed for MEDLINE]Related articles

New antiretroviral agents for the treatment of HIV infection.

Marks K, Gulick RM.

Curr HIV/AIDS Rep. 2004 Jun;1(2):82-8. Review.PMID: 16091227 [PubMed - indexed for MEDLINE]Related articles

Antiretroviral therapy: when and what to start-- an American perspective.

Wilkin TJ, Gulick RM.

Curr HIV/AIDS Rep. 2004 Jun;1(2):59-67. Review.PMID: 16091224 [PubMed - indexed for MEDLINE]Related articles

Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).

Zolopa AR, Lazzeroni LC, Rinehart A, Vezinet FB, Clavel F, Collier A, Conway B, Gulick RM, Holodniy M, Perno CF, Shafer RW, Richman DD, Wainberg MA, Kuritzkes DR.

Clin Infect Dis. 2005 Jul 1;41(1):92-9. Epub 2005 May 24.PMID: 15937768 [PubMed - indexed for MEDLINE]Related articles

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP.

AIDS. 2004 Dec 3;18(18):2391-400.PMID: 15622315 [PubMed - indexed for MEDLINE]Related articles

Case-control study of diabetes mellitus in HIV-infected patients.

Yoon C, Gulick RM, Hoover DR, Vaamonde CM, Glesby MJ.

J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1464-9.PMID: 15602124 [PubMed - indexed for MEDLINE]Related articles

Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.

Swanstrom R, Bosch RJ, Katzenstein D, Cheng H, Jiang H, Hellmann N, Haubrich R, Fiscus SA, Fletcher CV, Acosta EP, Gulick RM; AIDS Clinical Trials Group Protocol 359 Team.

J Infect Dis. 2004 Sep 1;190(5):886-93. Epub 2004 Jul 23.PMID: 15295692 [PubMed - indexed for MEDLINE]Related articles

New Antiretroviral Agents for the Treatment of HIV Infection.

Marks K, Gulick RM.

Curr Infect Dis Rep. 2004 Aug;6(4):333-339.PMID: 15265463 [PubMed - as supplied by publisher]Related articles

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group Study A5095 Team.

N Engl J Med. 2004 Apr 29;350(18):1850-61.PMID: 15115831 [PubMed - indexed for MEDLINE]Related articlesFree article

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.

Hicks C, King MS, Gulick RM, White AC Jr, Eron JJ Jr, Kessler HA, Benson C, King KR, Murphy RL, Brun SC.

AIDS. 2004 Mar 26;18(5):775-9.PMID: 15075512 [PubMed - indexed for MEDLINE]Related articles

Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.

Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM.

J Infect Dis. 2004 Apr 1;189(7):1176-84. Epub 2004 Mar 16.PMID: 15031785 [PubMed - indexed for MEDLINE]Related articles

Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.

Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greenberg M, Melby T, Raskino C, Rusnak P, Zhang Y, Spence R, Miralles GD.

J Infect Dis. 2004 Mar 15;189(6):1075-83. Epub 2004 Mar 2.PMID: 14999611 [PubMed - indexed for MEDLINE]Related articles

Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine.

Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, Isaacs R, Gonzalez C, McMahon D, Richman DD, Robertson M, Mellors JW.

AIDS. 2003 Nov 7;17(16):2345-9.PMID: 14571186 [PubMed - indexed for MEDLINE]Related articles

Antiretroviral Therapy: When and What to Start-- An American Perspective.

Wilkin TJ, Gulick RM.

Curr Infect Dis Rep. 2003 Aug;5(4):339-348.PMID: 12866986 [PubMed - as supplied by publisher]Related articles

New drugs for HIV therapy.

Gulick RM, Staszewski S.

AIDS. 2002;16 Suppl 4:S135-44. Review. No abstract available. PMID: 12699010 [PubMed - indexed for MEDLINE]Related articles

Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients.

Casau NC, Glesby MJ, Paul S, Gulick RM.

J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):494-8.PMID: 12679700 [PubMed - indexed for MEDLINE]Related articles

New antiretroviral drugs.

Gulick RM.

Clin Microbiol Infect. 2003 Mar;9(3):186-93. Review.PMID: 12667250 [PubMed - indexed for MEDLINE]Related articles